Lilly Permax Cardiac Valvulopathy Safety Warning Added To Labeling
Executive Summary
Lilly is updating Permax labeling to include a warning on cardiac valvulopathy incidence associated with the Parkinson's disease treatment
You may also be interested in...
Permax Patients Should Be Evaluated For Somnolence, Lilly Says
Lilly is updating Permax (pergolide) labeling to include a warning that the Parkinson's drug may cause patients to fall asleep without warning
Permax Patients Should Be Evaluated For Somnolence, Lilly Says
Lilly is updating Permax (pergolide) labeling to include a warning that the Parkinson's drug may cause patients to fall asleep without warning
Amarin/Elan Parkinson's deal
Amarin plans to file an NDA for rapid-dissolving selegiline formulation Zelapar in the first half of 2002 following the acquisition from Elan of U.S. rights to the Parkinson's treatment. London-based Amarin (formerly Ethical Holdings) will also promote the Parkinson's therapy Permax (pergolide) with 24 reps; the product generated sales of $40 mil. in 2000